The NOTCH1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population in which the NOTCH1 gene has been disrupted to eliminate canonical Notch signaling in a human B lymphocyte background. This heterogeneous loss-of-function system allows investigation of NOTCH1-dependent processes without clonal selection bias. The Raji host cell line is an EBV-positive Burkitt’s lymphoma line widely used in immunological and oncological studies, enabling dissection of NOTCH1’s role in B-cell malignancies.
Derived from a Burkitt’s lymphoma patient, Raji cells are B lymphocytes expressing typical mature B cell markers and serve as a model for B-cell signaling and lymphoma biology. Their aggressive proliferative phenotype and apoptosis resistance facilitate examination of Notch crosstalk with oncogenic pathways. This B-cell lineage is relevant for NOTCH1 studies, as activating NOTCH1 mutations occur in B-cell lymphomas like chronic lymphocytic leukemia and diffuse large B-cell lymphoma.
NOTCH1 encodes a transmembrane receptor cleaved by ADAM10/ADAM17 and gamma-secretase (including PSEN1) upon ligand binding, releasing the intracellular domain NICD. NICD associates with CSL/RBPJ and coactivators MAML1 and EP300 to transactivate targets HES1, HES5, HEY1, HEY2, MYC, and CCND1, while repressing P21. Ligands DLL4 and JAG1, and modulators NUMB and fringe glycosyltransferases regulate NOTCH1. Knockout prevents NICD production, silencing this transcriptional network and impairing proliferation and survival, consistent with NOTCH1’s oncogenic role in hematopoietic cells.
In Raji cells, NOTCH1 knockout is valuable for dissecting its contribution to B-cell lymphoma. Gain-of-function NOTCH1 mutations in B-cell malignancies promote growth and apoptosis resistance. The loss-of-function model enables evaluation of lymphoma cell dependency on Notch signaling and identification of synthetic lethal interactions. It permits assessment of cell cycle, apoptosis, and drug response, informing therapeutic strategies. Raji’s immunological features also support tumor-immune microenvironment studies.
Applications include studying Notch signaling in B-cell malignancies, testing gamma-secretase inhibitors like DAPT, and investigating immune differentiation. Assays: Western blot for NOTCH1/NICD, RT-qPCR for HES1 and MYC, flow cytometry (Annexin V, CFSE), Notch reporter luciferase, caspase-3 activity. RNA-seq reveals transcriptomic changes. These support drug sensitivity screens and functional genomics. For more information, please contact Ascent Research.
